Cell lines peripheral blood monocyte

Twenty years ago, a high-affinity-binding site for uPA was demonstrated on the surface of peripheral blood monocytes and cultured cells of the human histiocytic lymphoma cell line, U937 [46]. The expression of uPAR on the cell surface of many cell types has since then been demonstrated, including a variety of neoplastic cell lines as well as nonneoplastic cells such as neutrophils, macrophages, keratinocytes, placental trophoblasts, endothelial, and smooth muscle cells [7, 33, 47-51]. The human uPAR gene has been mapped to chromosome 19ql.3 [52]. 

RPR103611 (246) was tested in a panel of isolates and cell lines, including the monocytic cell line U-937 and peripheral blood lymphocytes. The IC50 values... 

Recruit volunteers who met entrance requirements 2. Screen botanical ingredients for inhibition of IL-1 p production 3. Pilot clinical evaluation of IL-1 inhibitory lead candidate botanicals from activity 2 Establishing a clinical genotyped database Human monocyte cell lines stimulated in vitro with LPS Clinical + laboratory assay of peripheral blood mononuclear cells (PBMCs), and plasma Adequate number of healthy subjects with CRP = 2-10 mg/L and stratified by IL1 composite genotype Select lead candidate botanicals based on IL-1 protein inhibitory dose compared to untreated cultures IL1 gene expression in PBMCs and ex vivo IL-1 production in plasma from test subjects after 2-week dosing of candidate botanicals... 

Some phenothiazines, the so-called half-mustard type, stimulated T-cell blast formation, presented a natural killer cell activity, via possibly the activation of monocytes and macrophages, and an antibody-dependent cellular cytotoxicity of human peripheral blood mononuclear cells, and also showed cytotoxicity against several human cancer cell lines. These phenothiazines also might induce an in vivo antimicrobial activity by possibly their host-mediated immuno-potentiation [146]. Phenothiazines did not demonstrate any apparent mutagenic activity, but they were rather antimutagenic. These data suggest the possible applicability of half-mustard type phenothiazines and benzo[a]phenothiazines to cancer chemotherapy. 

A basic understanding of normal hematopoiesis is needed before one can understand the pathogenesis of leukemia. The reader is referred to Chap. 98 for a detailed discussion of hematopoiesis. Normal hematopoiesis consists of multiple well-orchestrated steps of cellular development. A pool of pluripotent stem cells undergoes differentiation, proliferation, and maturation, to form the mature blood cells seen in the peripheral circulation. These pluripotent stem cells initially differentiate to form two distinct stem cell pools. The myeloid stem cell gives rise to six types of blood cells (erythrocytes, platelets, monocytes, basophils, neutrophils, and eosinophils), while the lymphoid stem cell differentiates to form circulating B and T lymphocytes. Leukemia may develop at any stage and within any cell line. 

Zalcitabine (2, 3 dideoxycytidine ddC) is a synthetic cytosine analog reverse-transcriptase inhibitor. It is active against HIV-I, HIV-2, and hepatitis B virus (HBV). The in vitro ICjo of zalcitabine against HIV-1 ranges from 2 nM in monocytes-macrophage cell lines to 0.5 pM in human peripheral blood mononuclear cells. Zalcitabine has considerably more antiretroviral activity in monocytes-macrophage cell lines than other nucleoside analogs, but the potential clinical utility of this observation is uncertain. 

Zidovudine (200 mg every 4 hours) is indicated in the management of patients with HIV infection who show evidence of impaired immunity. Trimethoprim-sulfamethoxazole, pyrimethamine, and acyclovir may be necessary for the management or prevention of opportunistic infections. Zidovudine (3 -azido-3 -deoxythymidine, commonly referred to as AZT) is a thymidine analog with antiviral activity against HIV-1, HIV-2, human T-lymphotropic (or leukemia) virus (HTLV)-I, and other retroviruses. Low concentrations (<0.001 to 0.04 pg/ml) inhibit acute HIV-1 infection in human T-cell lines and peripheral blood lymphocytes. Zidovudine is less active in human monocyte-macrophages or quiescent cells but inhibits HIV replication in human brain macrophages. Zidovudine is also inhibitory for HBV and EBV... 

---